Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation

American Journal of Hematology

Volumn 88, Issue 4, 2013, Pages 301-305

  Hammerstrom, Aimee E ^a   Howell, Joshua ^a   Gulbis, Alison ^a   Rondon, Gabriela ^a   Champlin, Richard E ^a   Popat, Uday ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ADULT; ADVERSE OUTCOME; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD PRESSURE REGULATION; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MEDICAL RECORD REVIEW; MENTAL DISEASE; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEIZURE; SURVIVAL; VISUAL DISORDER;

ADULT; AGED; BLOOD PRESSURE; DISEASE MANAGEMENT; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA; MALE; MIDDLE AGED; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84875597555     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23402     Document Type: Article

References (15)

1. Wong R, Beguelin GZ, de Lima M, et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2003;122:128-134.
2. Hinchey J, Caplan LR. A reversible posterior leukoencephalopathy syndrome - Reply. N Eng J Med 1996;334:1746-1746.
3. Stott VL, Hurrell MA, Anderson TJ. Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed. Int Med J 2005;35:83-90.
4. Wu Q, Marescaux C, Wolff V, et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation. Eur Neurol 2010;64:169-177.
5. Yamauchi A, Ieiri I, Kataoka Y, et al. Neurotoxicity induced by tacrolimus after liver transplantation: Relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 2002;74:571-572.
6. Yanagimachi M, Naruto T, Tanoshima R, et al. Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation. Clin Transplant 2010;24:855-861.
7. Misawa A, Takeuchi Y, Hibi S, et al. FK506-induced intractable leukoencephalopathy following allogeneic bone marrow transplantation. Bone Marrow Transplant 2000;25:331-334.
8. Kanekiyo T, Hara J, Matsuda-Hashii Y, et al. Tacrolimus-related encephalopathy following allogeneic stem cell transplantation in children. Int J Hematol 2005;81:264-268.
9. Tam CS, Galanos J, Seymour JF, et al. Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. Am J Hematol 2004;77:72-76.
10. Oliverio PJ, Restrepo L, Mitchell SA, et al. Reversible tacrolimus-induced neurotoxicity isolated to the brain stem. AJNR Am J Neuroradiol 2000;21:1251-1254.
11. Beitinjaneh A, McKinney AM, Cao Q, et al. Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011;17:300-308.
12. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009;4:481-508.
13. Steg RE, Kessinger A, Wszolek ZK. Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation. Bone Marrow Transplant 1999;23:959-962.
14. Moskowitz A, Nolan C, Lis E, et al. Posterior reversible encephalo syndrome due to sirolimus. Bone Marrow Transplant 2007;39:653-654.
15. Cutler C, Antin JH. Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: An update. Curr Opin Hematol 2010;17:500-504.